Drug Profile
Brensocatib - AstraZeneca/Insmed
Alternative Names: AZD 7986; INS-1007Latest Information Update: 09 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Insmed
- Class Amides; Anti-inflammatories; Antibronchitics; Nitriles; Oxazepines; Oxazoles; Small molecules
- Mechanism of Action Dipeptidyl peptidase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bronchiectasis; COVID 2019 infections
- Phase II Chronic obstructive pulmonary disease; Cystic fibrosis; Rhinosinusitis
- Phase I Hidradenitis suppurativa
- No development reported Granulomatosis with polyangiitis
Most Recent Events
- 05 Jan 2024 Insmed anticipates to launch Brensocatib In Bronchiectasis (Non-cystic fibrosis-related) in the Europe and Japan in the first half of 2026.
- 05 Jan 2024 Insmed anticipates to launch Brensocatib In Bronchiectasis (Non-cystic fibrosis-related) in the US in mid 2025
- 05 Jan 2024 Insmed plans a phase II trial in Hidradenitis Suppurativa (HS) in the second half of 2024